Another randomized, phase 2 trial also demonstrated improved two-year DFS and better tolerability in patients with EGFR-mutant stage IIIA NSCLC after adjuvant erlotinib compared with chemotherapy [10]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.